Molecular docking in the active site of PDE10A showed in Figure suggested a similar binding pose of baricitinib to the crystallized inhibitor (PDB ID: 5C1W), with a predicted p-stacking interaction with the Phe719 residue, crucial for biological activity. Additionally, among important regions for ligand binding is the occupation of a hydrophobic clamp formed by two phenylalanine residues, Phe719 and Phe686. Clinically, PDE10A inhibition is expected to decrease the risk for thrombosis, particularly in patients with PAH. Thus, the expected positive clinical impact of PDE10A inhibition on the risk of thrombosis is not in line with a potential link to an elevated thrombosis risk.